Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50 – 58 Baggot Street Lower, Dublin 2, Ireland
Xagrid 0.5 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsule. An opaque white hard capsule imprinted with S 063. |
Each hard capsule contains 0.5 mg anagrelide (as anagrelide hydrochloride).
Excipient(s) with known effect: Each hard capsule contains lactose monohydrate (53.7 mg) and anhydrous lactose (65.8 mg).
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production. |
| List of Excipients |
|---|
|
Capsule contents: Povidone (E1201) Capsule shell: Gelatin Printing ink: Shellac |
High-density polyethylene (HDPE) bottles with child-resistant closures and desiccant containing 100 capsules.
Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50 – 58 Baggot Street Lower, Dublin 2, Ireland
EU/1/04/295/001
Date of first authorisation: 16 November 2004
Date of latest renewal: 16 November 2014
| Drug | Countries | |
|---|---|---|
| XAGRID | Austria, Cyprus, Germany, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.